Selma Blair is returning to Southfield on Friday, May 16 to receive the key to the city and help raise money for MS support and local arts programs.

PRESS RELEASE MASITINIB SHOWS PROMISING NEUROPROTECTIVE EFFECTS IN NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE MODEL A NEW PUBLICATION IN THE SCIENTIFIC JOURNAL PLOS ONE, SHOWS THAT MASITINIB CAN ...

Three months of supplements with ellagic acid — an antioxidant — significantly eased fatigue, depression, and anxiety in MS ...

RRMS patients started on high-efficacy treatments may have less reduction in work capacity than those on moderate-efficacy DMTs, per a study.

Imprint, a Focused Research Organization building forensic immunology tools, aims to uncover the relationships between the immune system and chronic disease, including neuropsychiatric disordersNEW ...

A young woman has taken to TikTok to chronicle life with the debilitating illness and shares three warning signs you cannot ...

Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development for intranasal delivery. By modulating ...

Silo Pharma (NASDAQ: SILO) has partnered with Frontage Laboratories to conduct a 7-day safety and toxicology study of its lead asset, SPC-15, followi ...

ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, ...

MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...

I am not a doctor. I am a woman, one of millions who have sat across from a doctor, described my pain in excruciating detail, ...

Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery ...